:: Posted by American Biotechnologist on 03-16-2012
Merck, known outside the United States and Canada as MSD, today announced a collaboration to create the California Institute for Biomedical Research (Calibr), an independent, not-for-profit organization (501c3) established to accelerate the translation of basic biomedical research into innovative, new medicines to treat disease.
Calibr will be led by Peter G. Schultz, Ph.D., a world-renowned chemist and biotechnology entrepreneur. The Institute will offer academic scientists, around the world, a streamlined, efficient and flexible path for translating their biomedical research into novel medicines.
:: Posted by American Biotechnologist on 03-06-2012
Proteomics is about to take a big leap forward, that is if the NIH can help it.
Last week, the NIH put out a request for information aimed at determining how best to accelerate research in disruptive proteomics technologies. The organization is hoping that submissions will aim to greatly outperform current mass spec technologies and introduce an all new way of advancing proteomic questions.
According to the proposal:
The Disruptive Proteomics Technologies (DPT) Working Group of the NIH Common Fund wishes to identify gaps and opportunities in current technologies and methodologies related to proteome-wide measurements. For the purposes of this RFI, “disruptive” is defined as very rapid, very significant gains, similar to the “disruptive” technology development that occurred in DNA sequencing technology.
These are exciting times for the field of proteomics. Don’t be left behind! Click here to find out more on how to get involved today!
:: Posted by American Biotechnologist on 11-23-2011
GenomeWeb Daily News is reporting that a dozen Congressional leaders tasked with striking a bipartisan agreement to cut the federal deficit said yesterday that they have failed to reach a deal, and that failure would now trigger a plan that would, if enacted, cut research funding across the government by nearly 8 percent.
What impact do you believe this might have on your research activities?
Click here to read more.
:: Posted by American Biotechnologist on 08-25-2011
This past week the NIH announced that it was tightening its rules on financial conflict of interest for researchers receiving funding from drug and medical device companies. The new rules include the following revised regulations:
- Require investigators to disclose to their institutions all of their significant financial interests related to their institutional responsibilities.
- Lower the monetary threshold at which significant financial interests require disclosure, generally from $10,000 to $5,000.
- Require institutions to report to the PHS awarding component additional information on identified financial conflicts of interest and how they are being managed.
- Require institutions to make certain information accessible to the public concerning identified SFIs held by senior/key personnel.
- Require investigators to complete training related to the regulations and their institution’s financial conflict of interest policy.
According to the Washington Post, there are over 40,000 scientists who currently receive more than $5,000 in annual funding from the drug and medical device industries.
Despite the NIH’s move towards increasing financial transparency, not all watchdog groups are happy with the measure.
To read more on this story see the Washington Post article and the associated press release from the NIH.
:: Posted by American Biotechnologist on 08-10-2011
GenomeWeb News is reporting that the National Institute of Diabetes and Digestive and Kidney Diseases will award up to $15 million next year in grants to fund Diabetes Research Centers that will conduct a range of ‘omics-based and other interdisciplinary and translational research efforts.
Click here for more.